Acute Respiratory Infection
Conditions
Brief summary
The trial Safety, Pharmacokinetics and Preliminary Efficacy of herbal products for the treatment of acute respiratory viral infections including SARS-CoV2 in Uganda; Phase 2A Open Label Clinical Trial is currently being implemented under the Clinical Trials of Natural therapeutics Program. The trial sample size is 510, and the participants include adults (18 years or more) who fulfill the case definitions of acute respiratory infections (ARI), test positive for one of the target respiratory viruses, are negative for TB on GeneXpert; non-pregnant/non-breast-feeding females, have no history of hypersensitivity to any of the investigational products, and have given written consent to participate in the trial. The overall objective of the trial is to assess the safety, pharmacokinetics and preliminary efficacy of TazCoV and Vidicine for the treatment of acute respiratory viral infections including (SARS-CoV2, RSV and Influenza A/B) in Uganda. Primary objectives include: 1. To determine the safety and pharmacokinetics of TAZCOV and Vidicine herbal products among adult participants patients with acute respiratory infections including those due to laboratory-confirmed SARS-CoV2, RSV and Influenza A/B 2. To determine the extent of SARS-CoV2, RSV, and Influenza A/B viral clearance among adult participants patients with acute viral respiratory infection treated using TAZCOV and Vidicine 3. To establish time-to-remission of symptoms among participants patients with acute respiratory infections including those due to laboratory-confirmed SARS-CoV2, RSV and Influenza treated with TAZCOV or Vidicine 4. To evaluate disease progression among participants patients with acute respiratory infections including those due to laboratory-confirmed SARS-CoV2, RSV and Influenza treated with TAZCOV or Vidicine The end points include: Solicited and unsolicited side effects (mild, moderate, severe, adverse and serious adverse events), days to viral clearance (RT-PCR negativity) for those with a positive viral test at enrolment and time to presenting symptom resolution. The Pharmacokinetic endpoints include: the maximum concentration of IMP in plasma \[Cmax\], time taken for the IMP plasma concentration to reach maximum levels \[Tmax\] and time taken for the concentration of the IMP in the plasma or the total amount in the body to be reduced by 50%.
Interventions
DRUGTAZCOV
Herbal Syrup
DRUGVidicine
Herbal Syrup
Sponsors
Makerere University Lung Institute
MRC/UVRI and LSHTM Uganda Research Unit
Directorate of Government Analytical Laboratories
Makerere University College of Veterinary Medicine, Animal Resources and Bio-security
Makerere University Biomedical Research Centre
Natural Chemotherapeutics Research Institute
Makerere University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Intervention model description
A phase 2A open-label randomized controlled clinical trial
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
ALl adults who * fulfill ARI case definition * have signs and symptoms of ARI * test positive for one of the target respiratory viruses (SARS-CoV2, RSV, or Influenza A/B) * do not have symptoms suggestive of Pulmonary TB i.e cough for more than 2 weeks, drenching night sweats, evening fevers and marked weight loss. * can provide informed consent or have a surrogate or legally appointed representative to give consent
Exclusion criteria
* Severe acute respiratory illness (SARI)-defined as An acute respiratory illness with a history of fever or measured fever of ≥ 38 °C and cough and/or throat with onset within the past 10 days, requiring hospitalization or with SPO2≤92% * History of hypersensitivity to the investigational product or components therein * Conditions that may be regarded as contraindications to the investigational medicinal product include known allergic reactions and rashes to any herbal medicines and any untoward reactions to any herbal medications such as bleeding, headaches, high blood pressure, heart failure, seizures, agitation, etc. * Severe organ impairment (liver, kidney, brain, heart) * Inability to return for post-discharge follow-up * Females who are pregnant or intend to become pregnant or are breastfeeding during the trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Solicited and unsolicited side effects (mild, moderate, severe, adverse and serious adverse events). | 9 months | The outcome measures are cumulative incidences of solicited and unsolicited side effects (mild, moderate, severe adverse events) in the study arms |
| Time to presenting symptom resolution | 14 days | Will be assessed by time trends in clinical remission of signs and symptoms in the trial arms |
| Days to viral clearance (RT-PCR negativity) for those with a positive viral test at enrolment | 7 days | Will be assessed through ascertaining the proportion with negative PCR on days 3, 5 and 7 |
| Progression to severe-critical ARI requiring hospitalization, oxygen therapy and/or mortality | 14 days | To be measured by ascertaining the proportion progressing to severe ARI requiring hospitalization, oxygen therapy and/or mortality |
| Time taken for TazCoV and Vidicine plasma concentration to reach maximum levels [Tmax] | 14 days | To be measured by time to maximum concentration of TazCoV and Vidicine plasma \[Tmax\] |
Countries
Uganda
Outcome results
None listed